Drug
Aro Aat
Aro Aat: highest development phase Phase 2, developed by Arrowhead Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Arrowhead Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARO-AAT NCT03946449 | Phase 2 | Alpha 1-Antitrypsin Deficiency |
| ARO-AAT Injection NCT03362242 | Phase 1 | Alpha 1-Antitrypsin Deficiency |
Latest
No recent events.
Follow Aro Aat on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.